NAU

Navsari, India
Navsari, India

Time filter

Source Type

Data Demonstrate ADX-102 Activity Comparable to Topical Ocular Corticosteroids But Without Known Corticosteroid Side Effects LEXINGTON, MA--(Marketwired - May 17, 2017) - Aldeyra Therapeutics, Inc. ( : ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, presented the results of a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase 2 clinical trial of topical ocular ADX-102, a first-in-class aldehyde trap, as an Emerging Treatments paper at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Data from the trial demonstrated ADX-102 activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis (NAU). Unlike corticosteroid therapy, ADX-102 did not increase intraocular pressure, a major corticosteroid side effect that can lead to glaucoma, a potentially blinding chronic condition. Dr. John Sheppard, an internationally recognized expert in ocular inflammation, gave the presentation which is available on the investor relations page of the Aldeyra Therapeutics corporate website at ir.aldeyra.com. "The need to reduce exposure to the deleterious side effects of corticosteroids are well known within the ophthalmology community," commented Dr. John Sheppard. "The results of this important clinical trial suggest the potential therapeutic applicability of topical ocular ADX-102 as a novel and safe approach for the treatment of inflammation." Forty-five subjects were randomized equally to receive 0.5% ADX-102 four times daily, Pred Forte® (a corticosteroid) four times daily (tapered), or 0.5% ADX-102 four times daily and Pred Forte® twice daily (tapered). There were no statistical differences among all groups for the clinical endpoints, including anterior chamber cell count and ocular flare. ADX-102 was generally well tolerated and there were no serious adverse events, consistent with previous Phase 1 and Phase 2 clinical trials. ADX-102 produced clinically meaningful effects on anterior chamber cell counts (ACC) comparable to corticosteroid. After four weeks of therapy, 53% of ADX-102-treated patients achieved ACC Grade 0 (zero or one cells) versus 38% for that of corticosteroid-treated patients. Rescue medication was required in 20% of ADX-102-treated patients versus 38% of corticosteroid-treated patients. In the safety population, clinically significant elevations of intraocular pressure were observed in corticosteroid-treated patients but not in ADX-102-treated patients. Mean intraocular pressure increased in the corticosteroid group, but decreased slightly in the ADX-102 group. In April 2017, Aldeyra announced the initiation of a Phase 3 clinical trial of topical ADX-102 in NAU. The Phase 3 trial is expected to enroll up to 100 patients with active disease, randomized equally to receive either 0.5% topical ocular ADX-102 or vehicle for four weeks. Consistent with prior trials used for marketing registration, the primary endpoint will be the resolution of inflammation. Results of the trial are expected to be announced in the second half of 2018. Aldehyde mediators are thought to broadly induce inflammation, including allergic disease such as allergic conjunctivitis and autoimmune disease such as NAU. Thus, ADX-102 and other aldehyde sequestering agents represent a novel anti-inflammatory approach. In February 2016, Aldeyra reported positive Phase 2 data with topical ocular ADX-102 in allergic conjunctivitis. The Phase 2 results in NAU released in May 2016 and presented at ARVO suggest that ADX-102 is also active in autoimmune disease. "In both autoimmune and allergic ocular inflammation, we have demonstrated in our first series of controlled Phase 2 clinical trials that ADX-102's novel aldehyde trapping mechanism produces clinically relevant effects comparable to existing therapies, along with evidence of a safety profile that could become an important option for clinicians treating patients with inflammatory disease," commented David Clark, M.D., Chief Medical Officer of Aldeyra. "We look forward to the results from our Phase 2b clinical trial in allergic conjunctivitis in June of this year, and in addition, the results from our Phase 2a Dry Eye Syndrome clinical trial, expected in the third quarter of this year." About Aldeyra Therapeutics Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. ADX-102 has not been approved for sale in the U.S. or elsewhere. About Noninfectious Anterior Uveitis Noninfectious anterior uveitis is a rare, potentially blinding disease that may be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation in the front of the eye, pain, impaired vision, and photophobia. About Allergic Conjunctivitis Allergic conjunctivitis is a common allergic disease that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, lid swelling, and redness. About Dry Eye Syndrome Dry Eye Syndrome is a common inflammatory disease characterized by insufficient moisture and lubrication over the anterior surface of the eye. Symptoms may include ocular irritation, burning, stinging, visual fluctuations, blurring, and, in severe cases, corneal ulceration. In patients with Dry Eye Syndrome, aldehydes may contribute to ocular inflammation as well as the impairment of lipids (fats) that lubricate the ocular surface. Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Aldeyra's plans for its product candidates. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the "Risk Factors " and "Management's Discussion and Analysis of Financial Condition and Results of Operations " sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors that could delay the initiation or completion of clinical trials. In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


Climate change combined with overlapping high-intensity land uses are likely to create conditions detrimental to the recreation economy, wildlife habitat, water availability and other resources in hyper-arid landscapes, or drylands, in the future, according to a paper published recently in Ecosphere. Drylands are of concern because broad-scale changes in these systems have the potential to affect 36 percent of the world's human population. The findings are based on an analysis of trends and spatial data for the Colorado Plateau, a drylands region that covers parts of Arizona, Utah, Colorado and New Mexico, by researchers from Northern Arizona University and the U.S. Geological Survey. The research team examined the combined effects of climate change and human land use -- agriculture, recreation, energy development, mining and population growth -- on a range of ecosystem functions and landscape attributes. "Our approach offers a relatively simple method for scenario development that could be applied to a wide range of change agents, ecosystem services and regions," said lead author Stella Copeland, NAU Merriam-Powell Center post-doctoral scholar. "Tools such as these can be used to inform natural resource planning and management efforts in the United States and elsewhere." Results included projections for aridity that provide context for other findings. Trend data from 1985 to 2014 show the southern and central parts of the Colorado Plateau drying at a higher rate than northerly areas. When declines in precipitation are compared to the average from 1985-2014, the increase in aridity was about 17 percent for the region as a whole. The study examined four scenarios to estimate how climate change and overlapping land uses may influence ecosystem functions and landscape attributes. Although outcomes varied by scenario and characteristic, the recreation economy had the highest impacts for all scenarios; followed by vegetation and wildlife habitat and cultural and spiritual values; water availability; soil productivity; and cropland productivity. The findings suggest that the recreation economy is vulnerable to negative impacts associated with the high degree of spatial overlap between areas of high recreation intensity, aridification, and petroleum and renewable energy development. Though some recreation areas such as national parks are largely protected from energy development, many of them are surrounded by public and private lands with high potential for energy development and other land uses. "These results illustrate remarkably rapid growth in both recreation and energy development on the Colorado Plateau over the past few decades. The combined influences of these changes on natural resources and related recreational activity is unclear, especially in the context of increasing aridity," said John Bradford, a USGS research ecologist and co-author of the study. "Higher intensity land use and warming is likely to lead to increased conflict and added complexity for resource managers."


RAPID CITY, S.D., March 20, 2017 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-campus institution of higher learning, today announced that it intends to release financial results for its fiscal 2017 third quarter and nine months ended February 28, 2017, after the closing of the stock market on Wednesday, April 5, 2017. The Company will then discuss those results in a conference call on Thursday, April 6, 2017, at 11:00 a.m. ET. Accompanying Slide Presentation and Webcast The Company will also have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at www.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q3-2017. The webcast will be archived and accessible for approximately 30 days.  About National American University Holdings, Inc. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the central United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.


PHOENIX, Feb. 28, 2017 (GLOBE NEWSWIRE) -- A new test for Lyme Disease may prove to be the most accurate tool available for the difficult-to-diagnose disease, giving hope to thousands of undiagnosed and misdiagnosed patients, if funding can be found to move it through clinical study to production. The test, called LymeSeq™ is poised to transform the speed and precision of diagnosis over current tests. This test will detect multiple strains of Lyme bacteria, plus all major co-infections and non-Lyme causes of disease like Influenza and Staph. LymeSeq, developed by research scientists at Translational Genomics Research Institute (TGen), has been funded by Focus On Lyme. The test may represent a breakthrough in diagnosis and testing for Lyme disease, which are currently about 50 percent accurate. After five years shuttling her daughter specialists across the country and intense antibiotic treatments to battle this disease, Focus On Lyme Executive Director Tammy Crawford got in touch with TGen. Knowing the institute’s experience using genetic sequencing to identify pathogens like tuberculosis and E. coli, Crawford asked if TGen could do the same for Lyme disease and when they said yes, she personally funded the initial research.  The researchers are led by Dr. Paul Keim, the Executive Director of the Pathogen and Microbiome Institute and the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), as well as Director of the Pathogen Genomics Division TGen North in Flagstaff, Ariz. Dr. Keim is an internationally recognized expert in DNA-based research methods, a fellow of the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science. LymeSeq works by targeting and amplifying specific regions of the Lyme bacteria’s DNA as well as specific genes in related bacteria. That amplified DNA gets sequenced, then researchers determine the bacterial species present in the sample by searching for the DNA code specific to Lyme or other bacteria, explained Dr. David Engelthaler, Director of Programs and Operations at TGen North, and Director of the Public Health and Translational Genomics Center at the Pathogen and Microbiome Institute. “LymeSeq has the potential to transform emergency rooms and doctor’s offices world wide, said Holly Ahern, MS, MT (ASCP) and SUNY Adirondack associate professor of microbiology, and a member of the leadership team at Focus on Lyme. Dr. Richard Horowitz, author of "How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease,” said, “more than ever, we need an accurate test” referencing the National Science Foundation’s identification of Lyme disease as an emerging pandemic threat, siting the current “problematic two-tiered testing scheme,” for which LymeSeq shows promise of being “superior in every way.” With exciting early signs of high accuracy, the next step is to advance the test into human trials. Crawford’s team of volunteers has raised more than $301,730 towards a goal of $500,000 to bring the test to market. BHHS Legacy Foundation recently stepped forward with an additional $100,000 in grant funding. “With the development of any new medical advancement, the steps are long, arduous and expensive. But we’ve come so far in such a short period of time, we need your help to get us to the finish line,” Crawford said. “We are all volunteers. Every single penny we raise goes towards the research, we keep nothing back.” For more information visit www.focusonlyme.org. To donate, visit: www.focusonlyme.org/donate.


News Article | April 8, 2016
Site: boingboing.net

Tom writes, "Scientists at Northern Arizona U. use a home-made machine to create 'exotic ices.' They're simulating the surface of Pluto to help explain data and pictures sent to Earth by the New Horizons spacecraft." MIT planetary science grad student Alissa Earle is using New Horizons and ice-lab data to study the boundaries of Pluto’s now-famous “heart” feature. The outskirts of the heart show signs of pitted ice and also of warmer ice rising to the surface, like blobs in a lava lamp. “This is just one of the regions where results from the NAU ice lab can really help us better understand what is going on... The work done in the lab helps us better understand how these substances behave at Pluto temperatures and pressures, which in turn helps us understand what we are seeing in the images being sent back by New Horizons.” And there’s plenty yet to understand, says Lowell astronomer Will Grundy, who as co-investigator of NASA’s New Horizons team had input into designing the mission. Scientists have known the nature of Pluto’s composition for decades, but New Horizons showed how the stuff on the little world’s surface interacts to build mountains and dig valleys. “[It’s] wild speculation until you see it laid out on a scale of tens of kilometers,” Grundy says.


RAPID CITY, S.D., Dec. 21, 2016 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-campus institution of higher learning, today announced that it intends to release financial results for its fiscal 2017 second quarter ended November 30, 2016, after the closing of the stock market on January 4, 2017. The Company will then discuss those results in a conference call on Thursday, January 5, 2017, at 11:00 a.m. ET. Accompanying Slide Presentation and Webcast The Company will also have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at www.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q2-2017. The webcast will be archived and accessible for approximately 30 days. About National American University Holdings, Inc. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the central United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.


RAPID CITY, S.D., Oct. 05, 2016 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-campus institution of higher learning, today announced that on October 3, 2016, the Company’s Board of Directors declared a cash dividend in the amount of $0.045 per share on all shares of the Company’s common stock outstanding and of record as of the close of business on December 31, 2016, to be paid on or about January 13, 2017. The Company operates on a May 31st fiscal year. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.


RAPID CITY, S.D., Feb. 01, 2017 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-campus institution of higher learning, today announced that on January 28, 2017, the Company’s Board of Directors declared a cash dividend in the amount of $0.045 per share on all shares of the Company’s common stock outstanding and of record as of the close of business on March 31, 2017, to be paid on or about April 7, 2017. The Company operates on a May 31st fiscal year. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.


News Article | November 16, 2016
Site: www.prnewswire.com

DALLAS, Nov. 16, 2016 /PRNewswire-USNewswire/ -- National American University announced Tuesday that it has entered into a license agreement with RefactorU to utilize RefactorU's curriculum in an NAU intensive 10-week coding bootcamp to be offered at NAU's Lewisville campus located near Da...


News Article | September 28, 2016
Site: globenewswire.com

Company to host conference call on September 29, 2016, at 11:00 a.m. ET RAPID CITY, S.D., Sept. 28, 2016 (GLOBE NEWSWIRE) -- National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University (“NAU” or the “University”), a regionally accredited, proprietary, multi-campus institution of higher learning, today reported unaudited financial results for its fiscal 2017 first quarter ended August 31, 2016. Ronald L. Shape, Ed.D., President and Chief Executive Officer of the Company, stated, “We continue to remain focused on our various strategic initiatives for long-term growth and remain confident that our University is well positioned in a challenging environment. We are very pleased with the enrollment growth in our continuing education and workforce development programs, the growth in our graduate program, and the growth in our doctoral program.  However, the enrollment pressures in our undergraduate programs continued to be a factor for the summer term even though we have continued to adapt our operations appropriately while also placing greater emphasis on student engagement.   We are leveraging our operational flexibility and balance sheet to take advantage of opportunities within our market.  We continue to assist students impacted by schools that have closed or have announced that they are discontinuing enrollments.  Over the past year, NAU has worked to accept transfers from other institutions where students have been unable to complete their education.  We have worked closely with these individuals and new enrollees to highlight our academic programs and the commitment we have to our students’ success.  We have grown our continuing education enrollment, and are also expanding outside of the United States through accepting enrollments from students at Canadian institutions with which NAU partners.  We believe that the infrastructure we have built over the past year has begun to gain traction.  Overall, we are excited about the initiatives we continue to work on in FY 2017 and believe these opportunities will serve to strengthen the long-term foundation upon which NAU was built nearly 75 years ago.” Total NAU student enrollment for the summer 2017 term decreased 16.1% to 6,832 students from 8,139 during the prior summer term. Students enrolled in 57,800 credit hours compared to 70,621 credit hours during the prior summer term. The current average age of NAU’s students continues to be in the mid-30s, with those seeking undergraduate degrees remaining the highest portion of NAU’s student population. The following is a summary of student enrollment at August 31, 2016, and August 31, 2015, by degree level and by instructional delivery method: The Company, through its wholly owned subsidiary, operates in two business segments: the academic segment, which consists of NAU’s undergraduate, graduate, and doctoral education programs and contributes the primary portion of the Company’s revenue; and ownership in and development of multiple apartments and condominium complexes from which it derives sales and rental income. The real estate operations generated approximately 1.0% of the Company’s revenue for the quarter ended August 31, 2016. The Board of Directors declared a cash dividend in the amount of $0.045 per share on all shares of the Company’s common stock outstanding and of record as of the close of business on September 30, 2016, that will be paid on or about October 7, 2016. Management will discuss these results in a conference call (with accompanying presentation) on Thursday, September 29, 2016, at 11:00 a.m. ET. The Company will also have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at http://investors.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q1-2017. National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-campus institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first campus in Rapid City, South Dakota, and has since grown to multiple locations throughout the United States. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles. This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's business. Statements made in this release, other than those concerning historical financial information, may be considered forward-looking statements, which speak only as of the date of this release and are based on current beliefs and expectations and involve a number of assumptions. These forward-looking statements include outlooks or expectations for earnings, revenue, expenses or other future financial or business performance, strategies or expectations, or the impact of legal or regulatory matters on business, results of operations or financial condition. Specifically, forward-looking statements may include statements relating to the future financial performance of the Company; the ability to continue to receive Title IV funds; the growth of the market for the Company’s services; expansion plans and opportunities; consolidation in the market for the Company’s services generally; and other statements preceded by, followed by or that include the words “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions. These forward-looking statements involve a number of known and unknown risks and uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by those forward-looking statements. Other factors that could cause the Company’s results to differ materially from those contained in its forward-looking statements are included under, among others, the heading “Risk Factors” in the Company’s Annual Report on Form 10-K, which the Company filed on August 5, 2016, and in its other filings with the Securities and Exchange Commission.  The Company assumes no obligation to update the information contained in this release. The following table provides a reconciliation of net income attributable to the Company to EBITDA/LBITDA: EBITDA consists of income attributable to the Company, less income from non-controlling interest, plus loss from non-controlling interest, minus interest income, plus interest expense (which is not related to any debt but to the accounting required for the capital lease), plus income taxes, plus depreciation and amortization. The Company uses EBITDA as a measure of operating performance. However, EBITDA is not a recognized measurement under U.S. generally accepted accounting principles, or GAAP, and when analyzing its operating performance, investors should use EBITDA in addition to, and not as an alternative for, income as determined in accordance with GAAP. Because not all companies use identical calculations, the Company’s presentation of EBITDA may not be comparable to similarly titled measures of other companies and is therefore limited as a comparative measure. Furthermore, as an analytical tool, EBITDA has additional limitations, including that (a) it is not intended to be a measure of free cash flow, as it does not consider certain cash requirements such as tax payments; (b) it does not reflect changes in, or cash requirements for, its working capital needs; and (c) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements, or future requirements for capital expenditures or contractual commitments. To compensate for these limitations, the Company evaluates its profitability by considering the economic effect of the excluded expense items independently as well as in connection with its analysis of cash flows from operations and through the use of other financial measures. The Company believes EBITDA is useful to an investor in evaluating its operating performance because it is widely used to measure a company’s operating performance without regard to certain non-cash expenses (such as depreciation and amortization) and expenses that are not reflective of its core operating results over time. The Company believes EBITDA presents a meaningful measure of corporate performance exclusive of its capital structure, the method by which assets were acquired and non-cash charges, and provides us with additional useful information to measure its performance on a consistent basis, particularly with respect to changes in performance from period to period.

Loading NAU collaborators
Loading NAU collaborators